Cord Blood Registry Uses BioLife Solutions CryoStor Clinical Grade Freeze Media in the Storage of Umbilical Cord Tissue Stem Cells

BOTHELL, WA – April 15, 2015 – BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that Cord Blood Registry® (CBR®), the world's largest newborn stem cell company, uses BioLife's CryoStor clinical grade cryopreservation freeze media in its process for cryogenic storage of umbilical cord tissue stem cells.

Storage of umbilical cord tissue is a product currently offered by a limited number of cord blood banks throughout the world. While umbilical cord blood is a source of hematopoietic (blood) stem cells, umbilical cord tissue is a rich source of mesenchymal stem cells, which have the ability to differentiate into cells of the connective tissue including osteoblasts (bone-forming cells), chondrocytes (cartilage cells), and adipocytes (fat cells).

Geoffrey Crouse, President and Chief Executive Officer of CBR and a founding board member of the recently formed Cord Blood Association, remarked on the use of CryoStor by stating, "Families entrust CBR with their newborn cord tissue samples because of our dedication to and reputation for high quality. We insist on that same level of quality from our partners, which is why we utilize BioLife Solutions for the preservation of cord tissue."

Mike Rice, BioLife Solutions CEO, remarked, "CBR pioneered the storage of umbilical cord blood and tissue and is the established leader in personalized storage of newborn stem cells. We are very pleased to count CBR among our most highly valued customers and look forward to identifying opportunities to expand our relationship."

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company's proprietary HypoThermosol® and CryoStor® biopreservation media products are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's proprietary products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. This enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. For more information please visit, and follow BioLife on Twitter.